John C Bell

John C Bell

UNVERIFIED PROFILE

Are you John C Bell?   Register this Author

Register author
John C Bell

John C Bell

Publications by authors named "John C Bell"

Are you John C Bell?   Register this Author

100Publications

-Reads

Use of Precision-Cut Lung Slices as an Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy.

Mol Ther Methods Clin Dev 2018 Sep 4;10:245-256. Epub 2018 Aug 4.

Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.

View Article
September 2018

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

J Clin Invest 2018 Sep 10. Epub 2018 Sep 10.

Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA.

View Article
September 2018

Oncolytic viruses as engineering platforms for combination immunotherapy.

Nat Rev Cancer 2018 Jul;18(7):419-432

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article
July 2018

Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy.

Nat Rev Cancer 2018 May 4. Epub 2018 May 4.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article
May 2018

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Cancer Res 2018 Feb 19;78(4):922-937. Epub 2017 Dec 19.

UCSF Helen Diller Family Comprehensive Cancer Center, Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, San Francisco, California.

View Article
February 2018

Oncolytic Viruses: The Best is Yet to Come.

Curr Cancer Drug Targets 2018 ;18(2):109-123

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

View Article
January 2018

cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.

Trends Immunol 2018 01 19;39(1):44-54. Epub 2017 Aug 19.

Department of Integrative Oncology, BC Cancer Agency, Vancouver, Canada. Electronic address:

View Article
January 2018

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Mol Ther 2018 Jan 24;26(1):56-69. Epub 2017 Oct 24.

Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, ON, Canada. Electronic address:

View Article
January 2018

Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition.

Sci Transl Med 2018 Jan;10(425)

Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada.

View Article
January 2018

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.

Mol Ther Methods Clin Dev 2017 Dec 30;7:112-122. Epub 2017 Sep 30.

UPMC Hillman Cancer Center and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article
December 2017

Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma.

Int J Cancer 2017 09 21;141(6):1257-1264. Epub 2017 Jun 21.

Centre for Innovative Cancer research, Ottawa Hospital Research Institute, Ottawa, ON, KlH 8L6, Canada.

View Article
September 2017

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.

Mol Ther Oncolytics 2017 Sep 4;6:80-89. Epub 2017 Aug 4.

Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H4R2, Canada.

View Article
September 2017

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.

Cancer Cell 2017 08;32(2):133-134

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

View Article
August 2017

Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells.

Sci Rep 2017 Jul 11;7(1):5153. Epub 2017 Jul 11.

Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.

View Article
July 2017

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Oncoimmunology 2017 31;6(4):e1285992. Epub 2017 Jan 31.

National Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany.

View Article
January 2017

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Mol Ther Oncolytics 2016 16;3:16027. Epub 2016 Nov 16.

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

View Article
November 2016

Oncolytic viruses-immunotherapeutics on the rise.

J Mol Med (Berl) 2016 09 4;94(9):979-91. Epub 2016 Aug 4.

Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.

View Article
September 2016

Single-particle characterization of oncolytic vaccinia virus by flow virometry.

Vaccine 2016 09 8;34(42):5082-5089. Epub 2016 Sep 8.

University of Ottawa Flow Cytometry and Virometry Core Facility, Canada; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada. Electronic address:

View Article
September 2016

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells.

Mol Ther Oncolytics 2016 16;3:16005. Epub 2016 Mar 16.

Department of Oncology, Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada; Department of Surgery, Alberta Children's Hospital, Research Institute for Child and Maternal Health, Calgary, Alberta, Canada.

View Article
September 2016

Cell carriers for oncolytic viruses: current challenges and future directions.

Oncolytic Virother 2013 9;2:47-56. Epub 2013 Oct 9.

Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada; Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

View Article
August 2016

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Oncolytic Virother 2015 28;4:25-31. Epub 2015 Jan 28.

SillaJen Inc, Seoul, South Korea.

View Article
August 2016

Oncolytic Viruses: Therapeutics With an Identity Crisis.

EBioMedicine 2016 Jul 2;9:31-36. Epub 2016 Jul 2.

Turnstone Biologics, 787 Bank Street, Ottawa, Ontario K1S 3V5, Canada; Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada. Electronic address:

View Article
July 2016

Regulation of Macropinocytosis by Diacylglycerol Kinase ζ.

PLoS One 2015 23;10(12):e0144942. Epub 2015 Dec 23.

Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Rd, Ottawa, ON, K1H 8M5, Canada.

View Article
June 2016

Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis.

Mol Ther Oncolytics 2015 23;2:15013. Epub 2015 Sep 23.

Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada; Department of Anatomy & Cell Biology, Western University, London, Ontario, Canada; Department of Oncology, Western University, London, Ontario, Canada; Department of Obstetrics & Gynaecology, Western University, London, Ontario, Canada.

View Article
April 2016

Oncolytic Viruses: Exploiting Cancer's Deal with the Devil.

Trends Cancer 2015 Dec 21;1(4):266-277. Epub 2015 Nov 21.

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ONT, Canada. Electronic address:

View Article
December 2015

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Curr Opin Virol 2015 Aug 17;13:49-54. Epub 2015 Apr 17.

SillaJen Biotherapeutics, 450 Sansome St, Suite 650, San Francisco, CA 94111, United States.

View Article
August 2015

Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer.

Curr Opin Virol 2015 Aug 7;13:viii-ix. Epub 2015 Aug 7.

Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32605, USA. Electronic address:

View Article
August 2015

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Mol Ther 2015 Jun 25;23(6):1066-1076. Epub 2015 Mar 25.

Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Surgery, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.

View Article
June 2015

Going viral with cancer immunotherapy.

Nat Rev Cancer 2014 Aug 3;14(8):559-67. Epub 2014 Jul 3.

Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada; and the Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

View Article
August 2014

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Mol Ther 2014 Jul 3;22(7):1320-1332. Epub 2014 Apr 3.

Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:

View Article
July 2014

Taming measles virus to create an effective cancer therapeutic.

Authors:
John C Bell

Mayo Clin Proc 2014 Jul 14;89(7):863-5. Epub 2014 May 14.

Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address:

View Article
July 2014

Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

Mol Ther 2014 Jun 26;22(6):1188-1197. Epub 2014 Feb 26.

Cork Cancer Research Centre, University College Cork, Cork, Ireland. Electronic address:

View Article
June 2014

Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies.

Mol Ther Nucleic Acids 2014 Jun 3;3:e167. Epub 2014 Jun 3.

Department of Chemistry, University of Ottawa, Ottawa, Ontario, Canada.

View Article
June 2014

Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.

Circulation 2014 Apr 24;129(13):1397-406. Epub 2014 Jan 24.

Cardiovascular Division and Lillehei Heart Institute (H.W., X.X., J.F., D.K., X.L., X.H., R.J.B., Y.C.) and Pulmonary Division (P.B.), University of Minnesota Medical School, Minneapolis; Shanghai Tenth People's Hospital of Tongji University, Shanghai, China (X.L.); Institute of Molecular Medicine, Peking University, Beijing, China (X.H.); Ottawa Hospital Research Institute, Ottawa, ON, Canada (T.J.F., J.C.B.); and Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China (H.L.).

View Article
April 2014

Oncolytic vaccinia virotherapy for endometrial cancer.

Gynecol Oncol 2014 Mar 14;132(3):722-9. Epub 2014 Jan 14.

Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. Electronic address:

View Article
March 2014

Smac mimetics and innate immune stimuli synergize to promote tumor death.

Nat Biotechnol 2014 Feb 26;32(2):182-90. Epub 2014 Jan 26.

1] Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

View Article
February 2014

From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.

PLoS Pathog 2014 Jan 16;10(1):e1003836. Epub 2014 Jan 16.

Centre for Innovative Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada ; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

View Article
January 2014

Panorama from the oncolytic virotherapy summit.

Mol Ther 2013 Oct;21(10):1814-8

McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

View Article
October 2013

Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells.

Clin Cancer Res 2013 Sep 23;19(18):5104-15. Epub 2013 Jul 23.

Authors' Affiliations: Centre for Innovative Cancer Research, Ottawa Hospital Research Institute; Departments of Cellular and Molecular Medicine, Biochemistry, Microbiology, and Immunology, and Surgery, University of Ottawa, Ottawa, Canada; Department of Neurosurgery, The Second Hospital of Shandong University, Shandong, China; Targeted & Biological Therapies Group, Leeds Institute of Cancer Studies and Pathology, Leeds, United Kingdom; Department of Medical Laboratory Technology, University of Tabuk, Tabuk; and College of Applied Medical Sciences, Taibah University, Medina, Saudi Arabia.

View Article
September 2013

Exploiting tumor epigenetics to improve oncolytic virotherapy.

Front Genet 2013 Sep 20;4:184. Epub 2013 Sep 20.

Center for Innovative Cancer Research, Ottawa Hospital Research Institute Ottawa, ON, Canada ; Faculty of Medicine, University of Ottawa Ottawa, ON, Canada.

View Article
September 2013

Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.

Clin Cancer Res 2013 Jul 28;19(14):3832-43. Epub 2013 May 28.

Ottawa Hospital Research Institute, Center for Cancer Therapeutics, Ottawa, Ontario, Canada.

View Article
July 2013

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Sci Transl Med 2013 May;5(185):185ra63

Pusan National University and Medical Research Institute, Pusan National University, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, South Korea.

View Article
May 2013

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Mol Ther 2013 Apr 8;21(4):887-94. Epub 2013 Jan 8.

McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

View Article
April 2013

Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience.

Ann Surg Oncol 2012 Dec 18;19(13):4244-51. Epub 2012 Jul 18.

National Centre for Pseudomyxoma Surgery, Basingstoke and North Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.

View Article
December 2012

Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling.

J Virol 2012 Nov 5;86(22):12228-36. Epub 2012 Sep 5.

Institut Cavanilles de Biodiversitat i Biologia Evolutiva, Universitat de València, Spain.

View Article
November 2012

Viral quantitative capillary electrophoresis for counting and quality control of RNA viruses.

Anal Chem 2012 Nov 19;84(21):9585-91. Epub 2012 Oct 19.

Department of Chemistry, University of Ottawa, Ottawa, Ontario, Canada.

View Article
November 2012

Anti-Fab aptamers for shielding virus from neutralizing antibodies.

J Am Chem Soc 2012 Oct 9;134(41):17168-77. Epub 2012 Oct 9.

Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada.

View Article
October 2012

Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.

Int J Cancer 2012 Aug 11;131(3):E204-15. Epub 2012 Jan 11.

Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article
August 2012

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Curr Pharm Biotechnol 2012 Jul;13(9):1768-72

Jennerex Inc. San Francisco, CA, USA.

View Article
July 2012

Oncolytic virotherapy.

Nat Biotechnol 2012 Jul 10;30(7):658-70. Epub 2012 Jul 10.

Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

View Article
July 2012

The virus that came in from the cold.

Authors:
John C Bell

Sci Transl Med 2012 Jun;4(138):138fs17

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, and Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.

View Article
June 2012

Electrochemical differentiation of epitope-specific aptamers.

Anal Chem 2012 Mar 24;84(5):2548-56. Epub 2012 Feb 24.

Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada.

View Article
March 2012

A selectable and excisable marker system for the rapid creation of recombinant poxviruses.

PLoS One 2011 8;6(9):e24643. Epub 2011 Sep 8.

Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.

View Article
February 2012

Electrochemical sensing of aptamer-facilitated virus immunoshielding.

Anal Chem 2012 Feb 17;84(3):1677-86. Epub 2012 Jan 17.

Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada.

View Article
February 2012

Aptamer-based viability impedimetric sensor for viruses.

Anal Chem 2012 Feb 1;84(4):1813-6. Epub 2012 Feb 1.

Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada.

View Article
February 2012

Interfering with tumor pathways that augment viral oncolysis.

Authors:
John C Bell

Mol Ther 2011 Dec;19(12):2108-9

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article
December 2011

Viral quantitative capillary electrophoresis for counting intact viruses.

Anal Chem 2011 Jul 3;83(13):5431-5. Epub 2011 Jun 3.

Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada.

View Article
July 2011

Thunder and lightning: immunotherapy and oncolytic viruses collide.

Mol Ther 2011 Jun 19;19(6):1008-16. Epub 2011 Apr 19.

Targeted and Biological Therapies Group, Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, UK.

View Article
June 2011

Ex vivo infection of live tissue with oncolytic viruses.

J Vis Exp 2011 Jun 25(52). Epub 2011 Jun 25.

Center for Innovative Cancer Research, Ottawa Hospital Research Institute (OHRI).

View Article
June 2011

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Cytokine Growth Factor Rev 2010 Apr-Jun;21(2-3):85-9. Epub 2010 May 15.

Jennerex Inc., San Francisco, CA, USA.

View Article
September 2010

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Mol Ther 2010 Aug 15;18(8):1440-9. Epub 2010 Jun 15.

Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

View Article
August 2010